Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study

References

• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other societies on cardiovascular disease prevention and clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10(Suppl 1):S1–78
   Google Scholar
• European Heart Network. Statistical data about cardiovascular disease in Europe. Available from http://www.ehnheart.org/files/statistics%202005–092711A.pdf [Accessed 6 July 2005]
   Google Scholar
• World Health Organization. World Health Report 2003. Available from http://www.who.int/entity/whr/2003/en/index.html [Accessed 6 July 2005]
   Google Scholar
• Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256: 2823–8
   Google Scholar
• Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 1986;2:933–6
   PubMed Web of Science ®Google Scholar
• Stason WB. Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol. Am Heart J 1990;119:718–24
   PubMed Web of Science ®Google Scholar
• 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383–9
   Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–9
   Google Scholar
• LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57
   Google Scholar
• Collins R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT–LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757–67
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071–80
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20–8
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29–38
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–22
   Google Scholar
• Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245–55
   PubMed Web of Science ®Google Scholar
• Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254–7
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–16
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robbins SR, Collins D, et al. Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs HDL Intervention Trial Study Group. N Engl J Med 1999;341:410–18
   PubMed Web of Science ®Google Scholar
• Adult Treatment Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   PubMed Web of Science ®Google Scholar
• International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease: executive summary. Available from http://www.athero.org/download/guidelines.pdf [Accessed 10 May 2005]
   Google Scholar
• Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625–9
   PubMed Web of Science ®Google Scholar
• Sacks FM. Adherence to statin therapy: why aren’t we doing better? Am J Med 2002;113:685–6
   PubMed Web of Science ®Google Scholar
• de Velasco JA, Cosin J, Lopez Sendon JL, et al. [Secondary prevention of myocardial infarction in Spain. The PREVERSE study]. Rev Esp Cardiol 1997;50:406–15
   PubMed Web of Science ®Google Scholar
• Velasco JA. After 4S, CARE and LIPID – is evidence-based medicine being practised? Atherosclerosis 1999;147(Suppl 1):S39–44
   PubMedGoogle Scholar
• EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995–1001
   Google Scholar
• EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569–82
   Google Scholar
• EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554–72
   PubMed Web of Science ®Google Scholar
• Van Ganse E, Souchet T, Laforest L, et al. Effectiveness of lipid-lowering therapy. Br J Clin Pharmacol 2005;59:456–63
   PubMed Web of Science ®Google Scholar
• Van Ganse E, Souchet T, Laforest L, et al. Long-term achievement of therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study. Atherosclerosis 2005 July 19 [Epub ahead of print]
   Google Scholar
• Krobot KJ, Yin DD, Alemao E, et al. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil 2005;12:37–45
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Alemao E, Krobot K, et al. LDL-C goal attainment and cardiovascular hospitalization among CHD patients in Germany. Presented at European Atherosclerosis Society. Prague, Czech Republic (April 23–26, 2005)
   Google Scholar
• Esposti ED, Melilli LE, Alemao E, et al. A population-based cross-sectional study on treatment patterns for hypercholesterolemia in Ravenna, Italy. Session P112. Presented at the 5th International Congress on Coronary Artery Disease – From Prevention to Intervention. Florence, Italy (October 19–22, 2003)
   Google Scholar
• Esposti ED, Melilli LE, Alemao E, et al. Lipid testing and results in patients receiving lipid-lowering therapy in a northern region in Italy. Session P228. Presented at the 5th International Congress on Coronary Artery Disease – From Prevention to Intervention. Florence, Italy (October 19–22, 2003)
   Google Scholar
• García Ruiz FJ, Ibanez AM, Pérez-Jiménez F, et al. and the REALITY Study Group. Current lipid management and low cholesterol goal attainment in common daily practice in Spain: the REALITY Study. PharmacoEconomics 2004;22(Suppl 3):1–14
   Google Scholar
• Melilli LE, Alemao E, Yin, DD. Factors associated with cholesterol goal attainment in the United Kingdom: patient characteristics and management practices. Session 305 P2999. Presented at the European Society of Cardiology. Vienna, Austria (August 30–September 3, 2003)
   Google Scholar
• Yin DD, Melilli LE, Alemao E. Trends in management of hypercholesterolemia in the United Kingdom: primary care practice from 1998 to 2001. Session 301 P633. Presented at the 5th International Congress on Coronary Artery Disease – From Prevention to Intervention. Florence, Italy (October 19–22, 2003)
   Google Scholar
• Melilli LE, Alemao E, Yin DD. Persistency of lipid-lowering therapy in United Kingdom: primary care practices and associated factors. Session 305 P2998. Presented at the European Society of Cardiology. Vienna, Austria (August 30–September 3, 2003)
   Google Scholar
• Ose L, Skjeldestad FE, Bakken IJ, et al. Current management of hyperlipidemia in Norway and factors associated with cholesterol goal attainment. Presented at European Atherosclerosis Society. Seville, Spain (April 17–20, 2004)
   Google Scholar
• Lindgren P, Borgström F, Stålhammar J, et al. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil 2005 [in press]
   Google Scholar
• Carlsson Å, Borgström F, Stålhammar J, et al. Costs of care for patients treated with lipid-lowering drugs. PharmacoEconomics 2004;22(Suppl 3):25–35
   Google Scholar
• Goettsch WG, Yin DD, Alemao E, et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY–PHARMO study. Curr Med Res Opin 2004;20:1025–33
   PubMed Web of Science ®Google Scholar
• Márk L, Zámolyi K, Alemao E, et al. Cholesterol goal attainment among patients treated with lipid lowering drugs in Hungary. Session PCV32. Presented at EURO ISPOR Meeting 2004. Hamburg, Germany (October 24–26, 2004)
   Google Scholar
• Darioli R, Alemao E, Davies G, et al. Lipid management and cholesterol goal attainment in Switzerland: the Swiss review of Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Presented at European Atherosclerosis Society. Seville, Spain (April 17–20, 2004)
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502
   Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207–13
   PubMed Web of Science ®Google Scholar
• Cochran WG. Some methods for strengthening the common chi-square tests. Biometrics 1954;10:417–51
   Web of Science ®Google Scholar
• Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955;11:375–85
   Web of Science ®Google Scholar
• Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart 2002;88:203–6
   PubMed Web of Science ®Google Scholar
• Ito MK, Delucca GM, Aldridge MA. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Ther 2001;6:129–35
   Google Scholar
• Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002;89:50C–7C
   Google Scholar
• McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med 1997;157:1921–9
   Google Scholar
• Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–67
   PubMed Web of Science ®Google Scholar
• Olson KL, Tsuyuki RT. Patients’ achievement of cholesterol targets: a cross-sectional evaluation. Am J Prev Med 2003;25:339–42
   PubMed Web of Science ®Google Scholar
• Muls E, De Backer G, De Bacquer D, et al. LIPI-WATCH, a Belgian– Luxembourg survey on achievement of European Atherosclerosis Society lipid goals. Clin Drug Invest 2000;19:219–29
   Web of Science ®Google Scholar
• Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004;117:73–81
   PubMed Web of Science ®Google Scholar
• Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106–7
   PubMed Web of Science ®Google Scholar
• Denke MA. Coadministration of multidrug therapy to achieve lipid goals. J Am Osteopath Assoc 2004;104:17–22
   Google Scholar
• Pearson T, Denke M, McBride P, et al. Ezetimibe added to statin therapy reduces LDL-C and improves goal attainment in patients with hypercholesterolemia. Abstract presented at 2004 Scientific Session of the American College of Cardiology. New Orleans, La (March 7–10, 2004)
   Google Scholar
• Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672–8
   PubMed Web of Science ®Google Scholar
• Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447–55
   PubMed Web of Science ®Google Scholar
• Gagné C, Bays HE, Weiss SR, et al. Efficiency and safety of ezetimibe added to on-going statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084–91
   Google Scholar